Page last updated: 2024-11-08

wy 41770

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Wy 41770: produced no gastric irritation in rats; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID165241
SCHEMBL ID677773
MeSH IDM0124928

Synonyms (14)

Synonym
5h-dibenzo[a,d][7]annulen-5-ylideneacetic acid
wy-41770
wy 41770
4517-99-1
(5h-dibenzo(a,d)cyclohepten-5-ylidene)acetic acid
wy-41,770
acetic acid, 5h-dibenzo(a,d)cyclohepten-5-ylidene-
SCHEMBL677773
5h-dibenzo[a,d][7]annulen-5-ylidenacetic acid
(5h dibenzo[a,d]cyclohepten-5-ylidene)acetic acid
POBFODAHUPCAAG-UHFFFAOYSA-N
(5h-dibenzo[a,d]cyclohepten-5-ylidene)acetic acid
DTXSID70196409
(5h-dibenzo[a,d]-cyclohepten-5-ylidene) acetic acid

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The drug was rapidly and well absorbed in all four animal species."( Disposition of (5H-dibenzo [a,d]cyclohepten-5-ylidene)acetic acid in laboratory animals.
Schillings, RT; Sisenwine, SF,
)
0.13

Dosage Studied

ExcerptRelevanceReference
" Wy-41,770 induced superficial erosions only in the cecum 26 hr after a single oral dose of 250 or 500 mg/kg of the drug, progressing to ulcers after 5 days dosing with ultrastructural evidence of bacteria in the mucosa."( Mucosal lesions induced in the rat intestinal tract by the anti-inflammatory drug, Wy-41,770, a weak inhibitor of prostaglandin synthesis, contrasted with those from the potent prostaglandin inhibitor, indomethacin.
Rainsford, KD, 1988
)
0.27
" when dosed before sensitization."( Immunomodulating activity of Wy-41,770 (5H-dibenzo[A,D]cyclohepten-5-ylidene) acetic acid.
Carlson, RP; Datko, LJ; Lewis, AJ; O'Neill-Davis, L, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]